Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

All amounts are in U.S. dollars

QUEBEC CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and the full year ended December 31, 2008.

    2008 Highlights

    - February

      - First patients treated with AEZS-108 for a Phase 2 trial in advanced
        ovarian and endometrial cancers.

    - March

      - Patient dosing commenced with cetrorelix in the second efficacy study
        of the Phase 3 program in benign prostatic hyperplasia ("BPH").
      - Completion of the sale to Paladin Labs of the marketed product,
        Impavido(R) (miltefosine), for approximately $9.2 million.

    - April

      - Appointment of Juergen Ernst, as Interim President and CEO, the
        Company's Chairman of the Board at the time, following the departure
        of our former President and CEO;
      - Completion of patient recruitment for the first efficacy study of the
        Phase 3 program in BPH with cetrorelix.

    - May

      - First patients treated with cetrorelix for the safety trial of the
        Phase 3 program in BPH.

    - June

      - Completion of the sale of the Company's Quebec City property for a
        purchase price of $7.1 million.

    - September

      - Appointment of Juergen Engel, Ph.D., as Company President and CEO,
        succeeding Juergen Ernst who, at the same time, was appointed as
        Executive Chairman of the Company.

    - October and November

      - Completion of patient recruitment for the second efficacy trial of
        the Phase 3 program with cetrorelix in BPH.

      - Initiation of the second stage of patient recruitment for AEZS-108
        P
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 19, 2011 , , • ... MS drug with neuroprotective effects that does not cause,immunosuppression. ... the first,to be administered orally, whereas the few treatments ... significant side effects. • NeuroAdvan, the ...
... Mosquitoes die soon after a blood meal if certain ... at the University of Arizona has discovered. The ... the worldwide effort to curb mosquito-borne diseases like dengue ... blocked a cellular process known as vesicle transport, on ...
... dots made from cadmium and selenium degrade in soil, ... a University at Buffalo study has found. The ... Science and Technology , demonstrates the importance of learning ... -- interact with the environment after disposal, said Diana ...
Cached Biology Technology:Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3
(Date:4/15/2014)... fuel cell systems soon could be powering the forklifts ... costs and with faster refueling times than ever before, ... Hawaii Hydrogen Carriers (HHC). , The goal of the ... that can refuel at low pressure four to five ... forklift, giving hydrogen a competitive advantage over batteries for ...
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2
... birthday, according to new infant mortality statistics for 2003 ... , The infant mortality rates showed no significant improvement ... time since 1958. , In 2003, the infant ... births, which was statistically unchanged from the 2002 rate ...
... more trick to the amazing repertoire of carbon nanotubes ... cells. , Nanotubes, tiny hollow carbon filaments about one ... famed as one of the most versatile materials ever ... one-sixth as dense, able to conduct electricity better than ...
... mouse or a rat under stress and what does ... lucky. When people suffer nontraumatic stress they often head ... Syrian hamsters, which are normally solitary, are placed in ... at the Center for Behavioral Neuroscience at Georgia State ...
Cached Biology News:US infant mortality rate fails to improve 2Nanotubes used for first time to send signals to nerve cells 2Just like us, social stress prompts hamsters to overeat, gain weight 2Just like us, social stress prompts hamsters to overeat, gain weight 3Just like us, social stress prompts hamsters to overeat, gain weight 4
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting ... native protein. It reacts with free MMP-2 ... antibody buffered aqueous glycerol solution ... pH 7.4, containing 50% glycerol and 15 ...
Acetylcholinesterase from human and monkey....
Biology Products: